Welcome to our dedicated page for Kewaunee Scienti SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for details on Kewaunee Scientific’s latest laboratory furniture contracts or wondering how steel prices affect its margins? This SEC filings hub brings every disclosure together, so you can move from question to insight in minutes.
Start with the Kewaunee Scientific annual report 10-K simplified section: our AI pinpoints backlog shifts, segment revenue from fume hoods vs. modular systems, and geographic risk factors—no need to scan 200 pages. Prefer quarter-to-quarter trends? The Kewaunee Scientific quarterly earnings report 10-Q filing page pairs raw numbers with narrative summaries that highlight material cost swings and project pipeline updates.
Real-time alerts keep you ahead of ownership moves. Track Kewaunee Scientific insider trading Form 4 transactions the moment they hit EDGAR. Our dashboard also groups Kewaunee Scientific Form 4 insider transactions real-time by executive, making it easy to spot buying before key bids or product launches.
Need context on sudden announcements? The platform’s AI explains every Kewaunee Scientific 8-K material events explained entry—from facility shutdowns to leadership changes—in plain language. For governance aficionados, the Kewaunee Scientific proxy statement executive compensation tab links pay packages to performance metrics, while AI flags noteworthy changes in option grants.
Across all filings you’ll see quick links like “understanding Kewaunee Scientific SEC documents with AI” and “Kewaunee Scientific earnings report filing analysis,” designed for analysts, portfolio managers, and supply-chain watchers alike. Every document is time-stamped, searchable, and supported by concise AI-powered summaries that turn dense disclosures into clear action points.
Kewaunee Scientific Corp. (KEQU) – Form 4 insider filing, dated 27 Jun 2025
The filing reports an equity award granted on 25 Jun 2025 to Thomas David Hull III, the company’s President, Chief Executive Officer, and Board member. The award consists of 25,328 restricted stock units (RSUs) recorded in Table II with transaction code “A” (award/acquisition) at an exercise price of $0.00 because the units were granted, not purchased.
• Vesting mechanics: 50 % of the RSUs are service-based and vest in three equal annual tranches beginning 30 Jun 2026, contingent on continued employment. The remaining 50 % are performance-based and will vest only if undisclosed performance targets are met over a three-year period. Each vested unit converts into one share of KEQU common stock.
• Post-grant ownership: Following the transaction, Mr. Hull directly holds 25,328 derivative securities representing the right to receive an equivalent number of common shares.
No open-market purchase or sale occurred, so there is no immediate cash inflow/outflow for the insider and no direct trading signal for the market. The award aligns executive incentives with shareholder value but introduces potential future dilution equal to roughly 0.9 % of KEQU’s 2.8 million outstanding shares (based on the last reported share count; actual dilution will depend on vesting outcomes).
Kewaunee Scientific (KEQU) filed a Form 4 showing that Chief Financial Officer Donald T. Gardner III received an equity award of 9,047 restricted stock units on 06/25/2025. The grant is evenly split: 50% service-based RSUs vest in three equal annual installments beginning 06/30/2026, while 50% are performance-based and vest only if three-year performance goals are achieved. Following the transaction, the CFO beneficially owns 9,047 derivative securities. No open-market buys or sells of common shares were reported, and the filing contains no other material events.
Kewaunee Scientific Corp (KEQU) reported a Form 4 filing disclosing equity transactions for Douglas J. Batdorff, VP of Manufacturing Operations. On June 25, 2025, Batdorff was granted 4,528 Restricted Stock Units (RSUs) under the FY26 program.
The RSU grant is structured in two components:
- 50% Service-Based RSUs: Vesting in three equal annual installments starting June 30, 2026, contingent on continued employment
- 50% Performance-Based RSUs: Vesting subject to achieving performance goals over a three-year period
Each RSU represents the right to receive one share of Kewaunee Scientific common stock. The grant was made at $0 cost to the executive. The ultimate number of shares received will depend on continued employment and performance metrics over the three-year period.
Kewaunee Scientific (NASDAQ: KEQU) filed a Form 4 disclosing that Vice President-Information Technology Mandar Ranade was granted 4,392 restricted stock units (RSUs) on 25 June 2025.
The award converts to an equal number of common shares at a $0 exercise price. 50 % of the RSUs are service-based, vesting in three equal annual installments beginning 30 June 2026, while the remaining 50 % are performance-based and vest only if three-year performance goals are achieved. Following the grant, the reporting person beneficially owns 4,392 derivative securities. No shares were sold or otherwise disposed of.
Elizabeth D. Phillips, VP of Human Resources at Kewaunee Scientific Corp (KEQU), received a grant of 4,111 Restricted Stock Units (RSUs) on June 25, 2025. The RSU grant is structured in two parts:
- 50% Service-Based RSUs: 2,055.5 units vesting in three equal annual installments starting June 30, 2026, contingent on continued employment
- 50% Performance-Based RSUs: 2,055.5 units subject to three-year performance goals
The RSUs represent the right to receive an equivalent number of common stock shares upon vesting. The grant was made at $0 cost to the executive. Final vesting of performance-based units will depend on achievement of undisclosed performance metrics over the three-year period. This equity award aligns executive compensation with both long-term service and company performance goals.
Kewaunee Scientific (Nasdaq: KEQU) filed a Form 8-K on June 25 2025 to furnish Item 2.02 – Results of Operations and Financial Condition. The company released its fourth-quarter and fiscal-year results for the period ended April 30 2025 via a press release, attached as Exhibit 99.1.
The information is expressly treated as "furnished," not "filed," thereby avoiding Section 18 liability and limiting incorporation into future SEC documents unless specifically cited. No other reportable events were disclosed.
FAQ
What is the current stock price of Kewaunee Scienti (KEQU)?
What is the market cap of Kewaunee Scienti (KEQU)?
What is the core business of Kewaunee Scientific Corporation?
What types of products does the company offer?
How does Kewaunee Scientific generate revenue?
What industries are served by Kewaunee Scientific?
How is the company structured globally?
What distinguishes Kewaunee Scientific in the competitive market?
Has the company undertaken any significant strategic initiatives?
How does Kewaunee Scientific maintain product quality and innovation?
